Collectively, these results indicate that inhibition of wt-p53 in human prostate cancer reduces AIP4 levels to activate CXCR4/CXCL12 axis, ultimately leading to tumor cell bone metastasis (Figure 6C). Here, CXCR4 is linked to neoplasm.